FDCP
PROK icon

Foster Dykema Cabot & Partners’s ProKidney PROK Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-54
Closed -$104 – 456
2024
Q3 		$104 Buy
+54
New +$123 ﹤0.01% 511

Other funds holding PROK

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BU
Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Foster Dykema Cabot & Partners's PROK Position: Q4 2024 in Review

Foster Dykema Cabot & Partners sold out of ProKidney (PROK) in Q4 2024, closing a stake of 54 shares — an estimated $104 sold.

Foster Dykema Cabot & Partners first reported a position in PROK in Q3 2024 and held it in 1 quarter. The position peaked at $104 in Q3 2024. 74 funds tracked by Wall St. Rank hold PROK as of Q4 2024.

  • Foster Dykema Cabot & Partners reported no remaining ProKidney position as of Q4 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 54 ProKidney shares in Q4 2024, an estimated $104.
  • Foster Dykema Cabot & Partners first reported a position in ProKidney in Q3 2024 and held it in 1 quarter.
  • Foster Dykema Cabot & Partners's ProKidney position peaked at $104 in Q3 2024.
  • 74 funds tracked by Wall St. Rank held ProKidney as of Q4 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2024, filed 13 Feb 2025.